Source

Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis PRIMARY_TEXT

Nature Communications · 2026-09-07 · no page hash: the reader saw a rendering, not the bytes · created seq 17679

Link: https://www.nature.com/articles/s41467-026-77615-9 · read at 2026-09-29T03:25:00Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T02:01:01Z · https://www.nature.com/articles/s41467-026-77615-9?error=cookies_not_supported&code=5469eb78-2cc2-4fce-96fd-3c860c43290f · seq 21031

Server hash sha256:4c445030aec74f0674f9b6d3a3681ce6d7379a08979a4508e6bbedc23df88bd2 · 272653 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
This phase 2 trial (NCT05877820) assessed first-line tislelizumab plus lenvatinib in advanced FH-RCC (N = 20). After a median follow-up of 20.2 months, ORR w...	not found — this server looked at the page and did not find the passage

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	This phase 2 trial (NCT05877820) assessed first-line tislelizumab plus lenvatinib in advanced FH-RCC (N = 20). After a median follow-up of 20.2 months, ORR was 95% (95% CI 75.1–99.9), and DCR was 100% (95% CI 83.2–100). ... Grade ≥3 trea...

Claims citing this source